Cavli Wireless Is Set to Unveil the Next Generation of LPWAN-based IoT with C42GM Smart Cellular IoT Module at Embedded World 2022, Germany.
17.6.2022 13:31:00 EEST | Business Wire | Press release
Cavli Wireless will participate in the Embedded World 2022 edition in Nuremberg, Germany, from June 21-23, 2022. The Embedded World event is the world's biggest trade fair for everything Embedded, from electronic systems, distributed intelligence, the Internet of Things, e-mobility, energy efficiency, and much more. The company will be exhibiting its IoT connectivity solutions in hall 5, booth no: 5-362.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220617005168/en/
Powering the next generation of LPWAN IoT with Cavli C42GM Smart Cellular IoT Module (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the new launch of the C42GM LTE CAT M1/NB1/NB2 compatible Smart Cellular IoT Module, which can be deployed across the globe, making it an ideal solution for logistics, automotive, vehicle tracking systems, and more.
C42GM is a dual-mode LTE CAT M1/NB1/NB2 (upgradable to Release 14) compatible Smart Cellular Module, based on 3GPP Release 13, that comes with an integrated eSIM. C42GM has a battery life profile of ten years due to Deep Sleep Mode capability. It also comes with integrated GNSS and Sigfox radio capability that can equip OEMs to explore use cases that need the hybrid LPWAN approach. As John Mathew, Chief Technology Architect at Cavli Wireless, quoted, “the integrated eSIM coupled with pre-loaded global connectivity further cements the C42GM as the world's most powerful LPWAN-based cellular IoT module."
By virtue of the Hubble Stack Intelligence, C42GM can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT Management platform wherein a customer or a Cavli Support Engineer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
Due to Cavli’s strong operator partnerships in the EU, we have an extensive footprint across Europe for our local LTE as well LTE-M connectivity offering, which is unparalleled in the industry in terms of service quality & pricing.
Join Cavli Wireless on June 22 at 16:00 GMT and participate in the exhibitor's forum where Thomas Fesquet, Business Engagement Manager for Cavli Wireless will be unveiling C42GM for our European customers & technology partners visiting the Embedded World event. Watch this video by Cavli Wireless for more information https://www.youtube.com/watch?v=DfyRiYjpkdM
"The Embedded World 2022 event is the premier trade fair for technology companies from around the globe to present their flagship offerings," said Tarun Thomas George, Chief Operating Officer at Cavli Wireless. "We are beyond excited to be a part of this prestigious event, share the stage alongside industry heavyweights, and demonstrate to the world how Cavli Wireless is democratizing the Internet of Things."
About Cavli Wireless
Cavli Wireless designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded World Exhibition & Conference in Nuremberg offers the embedded community the opportunity to learn about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005168/en/
Contact information
Ajit Thomas, CMO, Cavli Wireless Inc
ajit@cavliwireless.com
+1-650-535-1150
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom